Status:
COMPLETED
Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients
Lead Sponsor:
University Health Network, Toronto
Conditions:
Vaccine Response Impaired
Immune Suppression
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will be a randomized, double-blind, placebo-controlled trial of a third dose of Moderna vaccine versus placebo. Participants will be those that have received two doses of mRNA-1273 COVID va...
Detailed Description
Solid organ transplant (SOT) recipients are at high risk of COVID-19 complications. The Moderna vaccine (mRNA-1273) has proven highly efficacious and safe in a phase III large, randomized controlled t...
Eligibility Criteria
Inclusion
- Solid organ transplant recipient who has previously received Moderna vaccine at 0 and 1 months
- Able to provide informed consent
Exclusion
- Anaphylaxis or allergic reaction to Moderna vaccine
Key Trial Info
Start Date :
May 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2021
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04885907
Start Date
May 25 2021
End Date
August 30 2021
Last Update
August 2 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network, Toronto General Hospital
Toronto, Ontario, Canada, M5G 2N2
2
University Health Network, Toronto General Hospital, Multi-Organ Transplant
Toronto, Ontario, Canada, M5G2N2